AstraZeneca PLC vs μ
μκ°μ λ°λ₯Έ μκ°μ΄μ‘ λΉκ΅
AstraZeneca PLC
$248.3B
μμ #59
μ
$253.9B
μμ #57
μκ°μ λ°λ₯Έ μκ°μ΄μ‘
μ£Όμ μκ°
- AstraZeneca PLCμ΄(κ°) 2015λ κΉμ§ μμ(λ₯Ό) μΆμνμ΅λλ€
- μμ΄(κ°) 2016λ κΉμ§ AstraZeneca PLCμ(λ₯Ό) μΆμνμ΅λλ€
- AstraZeneca PLCμ΄(κ°) 2019λ κΉμ§ μμ(λ₯Ό) μΆμνμ΅λλ€
- μμ΄(κ°) 2026λ κΉμ§ AstraZeneca PLCμ(λ₯Ό) μΆμνμ΅λλ€
μ°λλ³ λΉκ΅
| μ°λ | AstraZeneca PLC | μ | μ λ |
|---|---|---|---|
| 2026 | $248.3B | $253.9B | μ |
| 2025 | $282.2B | $200.1B | AstraZeneca PLC |
| 2024 | $196.9B | $163.8B | AstraZeneca PLC |
| 2023 | $198.1B | $165.2B | AstraZeneca PLC |
| 2022 | $195.3B | $137.5B | AstraZeneca PLC |
| 2021 | $163.9B | $102.0B | AstraZeneca PLC |
| 2020 | $136.9B | $79.4B | AstraZeneca PLC |
| 2019 | $132.8B | $126.9B | AstraZeneca PLC |
| 2018 | $97.9B | $117.8B | μ |
| 2017 | $85.9B | $127.4B | μ |
| 2016 | $64.5B | $97.2B | μ |
| 2015 | $76.6B | $75.8B | AstraZeneca PLC |
| 2014 | $76.2B | $104.0B | μ |
| 2013 | $61.7B | $105.4B | μ |
| 2012 | $46.3B | $96.6B | μ |
| 2011 | $42.7B | $97.5B | μ |
| 2010 | $40.3B | $85.0B | μ |
| 2009 | $38.9B | $72.3B | μ |
| 2008 | $32.3B | $59.8B | μ |
| 2007 | $32.3B | $90.8B | μ |
| 2006 | $39.1B | $73.6B | μ |
| 2005 | $34.5B | $61.6B | μ |
| 2004 | $25.2B | $54.7B | μ |
| 2003 | $32.9B | $47.8B | μ |
| 2002 | $23.4B | $38.4B | μ |
| 2001 | $30.5B | $41.4B | μ |
| 2000 | $33.1B | $49.9B | μ |
| 1999 | $25.7B | $48.8B | μ |
| 1998 | $27.2B | $37.6B | μ |
| 1997 | $21.4B | $41.3B | μ |
| 1996 | $16.3B | $31.6B | μ |
| 1995 | $11.1B | $25.1B | μ |
| 1994 | $7.5B | $18.3B | μ |